Portfolio Company Growth Diagnosis: Is Marketing the Constraint, or Just Where It Shows Up?

The most expensive mistake across a portfolio is funding the wrong fix.

Let’s be honest: when a portfolio company’s growth stalls, marketing is the first thing your team points at. It’s the most visible line on the P&L. There’s a dashboard, an agency, a budget, sometimes a name attached to it. So it takes the blame, and it usually gets the next check written against it.

What I’ve found after years of sitting across the table from operators is that the pattern repeats itself with almost no variation. Marketing absorbs the blame at one company, and the fix gets funded. Months later, the number hasn’t moved, because the real constraint was never in marketing. It was in the sales process, the market position, or who actually owned the growth number. At one company, aiming at the wrong wall costs you a quarter. Across a portfolio, doing it at two or three companies at once is a capital allocation problem the board will eventually ask you to explain.

Your job as an operator isn’t to fix marketing at every company you hold. It’s to know, before you deploy another dollar, which companies have an actual marketing constraint and which ones have something else wearing a marketing costume.

The reliable way to do it is a neutral, executive-level read, not a guess.

The symptom shows up in marketing. The constraint usually sits somewhere else.

Here’s the hard truth: the most visible part of a system is rarely the part that’s broken. A car that won’t start might have a dead battery, or it might be out of fuel. The dashboard light tells you where to look first, not what’s actually wrong. Marketing is that dashboard light at every company you hold. It signals that something is off. It doesn’t name the cause.

This is why diagnosis, not marketing, is the real skill at the portfolio level. Most operators move straight to solutions, because solutions feel like progress and diagnosis feels like a delay. That instinct is how good operators are wired. A fast decision isn’t the same as a strong one. Aiming at the wrong wall quickly is an expensive way to be wrong, and it gets more expensive when you’re running the same reflex across several companies. Growth depends on positioning, demand, sales, retention, governance, and leadership working together. When it stalls, the cause can sit in any one of them. Marketing is one test among several, not the whole exam.

I wrote about the single-company version of this same discipline a while back: what a real diagnosis finds that a marketing audit never will. Worth a look if you want the founder-facing case for why an audit and a diagnosis are not the same thing.

What a real diagnosis requires, and why it’s an executive function

A determination like this doesn’t come from a scorecard or a dashboard review. It comes from someone who has run marketing as a P&L-connected function and knows the difference between an agency doing good work against a bad strategy and a strategy that was never viable. That’s full-service marketing leadership, applied as a diagnostic discipline rather than an ongoing execution retainer. In my experience, the operators who get this right treat the read itself as a governed process: fixed scope, fixed timeline, a written determination at the end, not an open-ended engagement.

Where the read finds that senior marketing capability is genuinely the gap, but a full-time executive isn’t justified at that company’s size, fractional leadership on a governed basis gives you an owner who installs the system and stands behind the number, without a full salary on every cap table. Match the level of leadership to what the diagnosis actually found. Don’t buy capability you don’t need, and don’t underfund a real gap because a mid-level hire was cheaper on paper.

The Misdiagnosis Map: reading the same symptom differently across your portfolio

Here’s the part a single-company founder doesn’t need and an operator does. You’re pattern-matching across companies, and the same visible symptom can point to a different real constraint at each one. Use this map to catch the reflex fix before you fund it, and to name the right first move instead.

The discipline is reading the symptom correctly before spending against it. Two companies with the same falling-leads chart can need two completely different decisions. The ‘no owner of the growth number’ pattern shows up so often that I wrote a longer piece on how that ownership gap actually forms inside a single company, if you want the mechanics behind it.

Five questions to run at each company before you deploy capital

Before anyone at a portfolio company hires a CMO, replaces an agency, or raises the budget, run the same five questions at each one, so you’re comparing them on the same terms.

• If this company doubled marketing output tomorrow, are you confident revenue would follow? Hesitation means the constraint is probably not volume.
• Where did the last several customers actually come from? Referrals, rather than an intentional channel, mean the constraint may sit upstream of marketing.
• When deals are lost, why? Poor fit points to strategy or positioning. Follow-up or price points to sales. Neither is fixed by more marketing.
• Can one person tie marketing spend to revenue without a long meeting? If not, the constraint may be governance, not the work.
• Has marketing ever worked here, and what changed? A period that worked, followed by a stall, usually points to a system or leadership change, not a broken channel.

Where the answers keep pointing outside marketing, that’s your signal. The budget you were about to approve would have treated the symptom and left the constraint in place.

Opinion versus determination: the standard your investment committee should hold

There’s a difference between an opinion and a determination, and it matters most right here. An opinion says, “I think it’s marketing,” or “I think they need a new agency.” A determination says, in writing, where the constraint sits and why, with enough reasoning that you could hand it to the board. One is a guess with a confident voice. The other is decision-grade clarity you can defend when you’re allocating capital across a portfolio.

This is what the Executive Marketing Readiness Review is built to produce: a 30-day executive diagnostic that names whether marketing leadership, governance, structure, or another upstream constraint is actually limiting growth at a given company, delivered as a written determination, not a set of impressions. It reads the whole system, not just the visible part. It asks who owns growth, whether spending is tied to revenue with executive discipline, and whether the real constraint is leadership rather than tactics, a distinction I go into in more depth elsewhere.

Every expensive marketing mistake shares one feature: the company acted before it knew the constraint. It hired a CMO to fix a sales problem. It fired an agency that was executing a flawed strategy well. It raised spending on a channel that was never the issue. A small, neutral diagnosis before a large, committed decision is decision insurance. It’s how you avoid funding the wrong fix, one company at a time, across the whole portfolio.

So before you approve the next hire, exit a leader, or raise a budget at any of your companies, answer the only question that makes the decision safe: where is the constraint, really? We cover this discipline regularly on the CMO Strategy Pros blog, if you want more of this thinking before your next capital decision.